Alterity Therapeutics (ATHE) EBIT Margin (2016 - 2019)

Alterity Therapeutics' EBIT Margin history runs 4 years deep, the most recent figure standing at 218.14% for Q4 2019.

• In Q4 2019, EBIT Margin fell 14419.0% year-over-year to 218.14%; the TTM figure through Dec 2019 stood at 123.14% (changed N/A YoY), while the FY2024 annual figure was 0.0%, changed 0.0% from the prior year.
• EBIT Margin was 218.14% for Q4 2019 at Alterity Therapeutics, down from 73.95% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 73.95% in Q4 2018 to a low of 308.48% in Q4 2017.
• Historically, EBIT Margin has averaged 173.96% across 4 years, with a median of 156.71% in 2019.
• The sharpest annual moves came in 2017 and 2018: EBIT Margin tumbled 21319 bps in 2017, then surged 23453 bps in 2018.
• A 4-year view of EBIT Margin shows it stood at 95.29% in 2016, then sank by 224 bps to 308.48% in 2017, then soared by 76 bps to 73.95% in 2018, then plunged by 195 bps to 218.14% in 2019.
• The last three EBIT Margin figures came in at 218.14% (Q4 2019), 73.95% (Q4 2018), and 308.48% (Q4 2017), per Business Quant data.